Fitish RX Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A treatment menu is not a clinical evidence file. That distinction matters at Fitish RX, where compounded semaglutide with B6, injectable tirzepatide, oral tirzepatide tablets, and a separate microdosing program appear under one telehealth brand. The offerings differ in formulation, route, stated purpose, and billing description. Evidence associated with an ingredient name cannot automatically establish results for every product carrying that name, much less for the clinic delivering it.

Public pages consulted October 19, 2026, describe a cash-pay service with online intake, licensed-provider review, medication conditional on approval, shipping, and ongoing communication. They also disclose important regulatory limits. This review separates those documented service promises from clinical research and identifies the practical gaps: unnamed pharmacies, unconfirmed geographic coverage, incomplete payment and cancellation terms, and no documented outcomes for Fitish RX’s own preparations. It evaluates public documentation, not firsthand care or independently verified clinical performance.

At a glance

Clinical organization: The privacy notice identifies Fitish, LLC and DrTelx, the affiliated professional entity whose licensed providers deliver care through the site.
Sources: [7]
Semaglutide price: Compounded semaglutide + B6 costs $219 for a monthly supply, including consultation, medication if approved, and shipping; no separate consultation or membership fees are advertised.
Sources: [8]
Tirzepatide options: Compounded injectable tirzepatide and oral tirzepatide tablets are each advertised at $339 for a monthly supply, including consultation, medication if approved, and shipping.
Sources: [14] [11]
Microdosing distinction: The separate program lists semaglutide at $179 and tirzepatide at $269 per 28-day supply, although another statement calls the supply monthly; its stated purpose is wellness and cosmetic support, not weight management.
Sources: [15]
Regulatory disclosure: Fitish RX states that compounded oral tirzepatide is not FDA approved and that no FDA-approved oral tirzepatide product is available.
Sources: [11]

Start with the product, not the ingredient name

Fitish RX’s menu raises several distinct evidence questions. Its semaglutide offering includes B6. Its tirzepatide offerings include both a subcutaneous injection and oral tablets. Microdosing sits in a separate program with a different stated purpose. These are not interchangeable descriptions of one treatment. A useful review must preserve those distinctions rather than treating every option as though it has the same research record.

The oral tirzepatide page is notably explicit: it says there is no FDA-approved oral tirzepatide product and describes its compounded tablets as not FDA approved. The semaglutide page likewise acknowledges that compounded medications do not undergo FDA review for safety, effectiveness, or manufacturing quality. Those disclosures are meaningful, but they do not themselves establish how a particular preparation performs.

FDA approval belongs to a specific product, not to Fitish RX, an affiliated clinical entity, or a pharmacy. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not prove clinical inequivalence. Our guide to approved medicines and compounded preparations explains why both regulatory status and formulation-specific evidence matter.

Fitish RX’s documented options and the distinctions to preserve
Offering	Advertised base price	Important qualification
Compounded semaglutide + B6	$219 per monthly supply	Medical evaluation and prescription required; consultation, medication if clinically approved, and shipping included.
Compounded injectable tirzepatide	$339 per monthly supply	Subcutaneous presentation; consultation, medication if clinically approved, and shipping included.
Oral tirzepatide tablets	$339 per monthly supply	Not FDA approved; consultation, medication if clinically approved, and shipping included.
Microdosing semaglutide	$179 per 28-day supply	Also described as monthly elsewhere; separate wellness/cosmetic program; no additional discounts.
Microdosing tirzepatide	$269 per 28-day supply	Medical evaluation and prescription required; not presented as a weight-management program.

Sources: [8] [14] [11] [15] [1]

What clinical trials can—and cannot—add

The relevant clinical context includes randomized trials of studied subcutaneous semaglutide and tirzepatide regimens. STEP 1 studied adults with obesity or overweight plus a weight-related condition, without diabetes, over 68 weeks. SURMOUNT-1 studied adults with obesity or overweight plus a weight-related complication, excluding diabetes, over 72 weeks. Neither was a study of Fitish RX’s service or its dispensed preparations.

These studies provide evidence about the interventions actually tested, not a transferable success rate for this provider. STEP 1 was funded by Novo Nordisk; SURMOUNT-1 was funded by Eli Lilly. Gastrointestinal tolerability and treatment discontinuation were part of their findings. Readers examining the original research can use our separate guides to STEP 1 and SURMOUNT-1 without turning two different trials into a head-to-head ranking.

The public documentation reviewed here does not supply a clinical trial of Fitish RX’s semaglutide-plus-B6 preparation, oral tirzepatide tablets, or microdosing program. It also does not establish provider-specific average outcomes. Shared ingredient language or a claim about mechanism cannot bridge those gaps. The practical question is what evidence supports the exact formulation, route, and intended use being offered—not simply whether the ingredient has appeared in a successful trial.

Sources: [3] [4] [8] [11] [15]

Who reviews an application and provides care

Fitish RX describes itself as a telehealth wellness clinic. Its website terms identify FITISH as the site operator, while the health privacy notice identifies Fitish, LLC together with DrTelx. That notice assigns care delivery to licensed providers associated with DrTelx. This is useful organizational information, but naming an affiliated entity is not the same as independently verifying individual clinicians’ credentials, professional roles, or state authorization.

The advertised entry point is a short online intake about health and goals. A licensed provider reviews the information and, if treatment is clinically appropriate, may prescribe. The site describes virtual evaluation without in-person visits. Its weight-management program is for adults whose BMI and medical history satisfy clinical criteria, and its privacy policy says it does not knowingly provide services to minors under 18.

The consulted pages do not provide numerical BMI thresholds, a complete screening protocol, or laboratory requirements. Nor do they establish a state-by-state service area. The terms reserve the ability to limit sales by geography or jurisdiction, which is not evidence of nationwide availability. Before submitting payment, readers should establish whether care is available in their state and what additional information or testing the reviewing clinician may require.

Sources: [13] [7] [9] [5] [14] [12] [8]

Microdosing has a separate purpose—and an unresolved evidence gap

Fitish RX’s dedicated microdosing page says the program is intended for general wellness and cosmetic support only, not weight loss or weight management. Elsewhere, its GLP-1 pages suggest that some people below the standard program’s BMI threshold may be candidates after clinical review. That creates a presentation tension: the alternative appears alongside weight-management eligibility information, but its own page expressly describes a different purpose.

The site’s references to metabolic, appetite, longevity, or cosmetic benefits should be read as provider marketing claims, not demonstrated outcomes in the consulted documentation. Neither the STEP 1 nor SURMOUNT-1 findings establish the effectiveness of this microdosing program. A lower-dose description also does not, by itself, establish a lower adverse-effect rate. The appropriate evidence question concerns the actual protocol and intended outcome, not the reassuring sound of the word microdosing.

Pricing also needs clarification. The page opens with a monthly-supply description and a starting price of $179, but lists semaglutide at $179 and tirzepatide at $269 for a 28-day supply. Twenty-eight days is not a calendar month. The program excludes additional discounts because Fitish RX says its rate is already discounted. Readers need the actual supply interval, billing schedule, and included services confirmed rather than borrowing assumptions from the standard programs.

Sources: [15] [14] [3] [4]

Published prices are concrete; payment commitments are less clear

Fitish RX says it does not accept insurance and operates as a cash-pay telehealth service. Its standard semaglutide price is $219 per monthly supply; injectable tirzepatide and oral tirzepatide tablets are each $339 per monthly supply. Each includes the provider consultation, medication if approved, and shipping. The semaglutide and injectable tirzepatide pages expressly say there are no separate consultation or membership fees. Clinical approval remains a condition of medication access.

Semaglutide bundles are advertised at $195 per month for three months and $175 per month for six months. Both tirzepatide presentations advertise $305 per month for three months and $270 per month for six months. Fitish RX labels these as 10% and 20% savings and says bundle pricing is applied during intake. Those are the provider’s advertised figures; the percentage labels should not substitute for reading the actual dollar amounts.

The consulted documentation does not establish whether bundles require upfront collection, what total is payable at enrollment, or whether a minimum commitment applies. A package duration does not establish the quantity shipped at once. Prices may change without notice under the website terms. Laboratory work, administration supplies, and outside services are not clearly addressed, so the advertised inclusions should not be stretched into a promise that every possible treatment-related expense is covered.

Sources: [8] [14] [11] [5] [9]

Pharmacy and delivery claims need operational detail

The semaglutide page says preparation occurs at a state-licensed sterile compounding pharmacy. The injectable tirzepatide page describes discreet shipment from a licensed compounding pharmacy on a monthly cadence. These are provider statements, not independently verified pharmacy findings. The consulted pages do not name the dispensing pharmacies or supply license details, leaving readers unable to identify the particular organization responsible for their medication before further inquiry.

Monthly shipping does not establish a delivery date, a subscription contract, or shipment of an entire bundle at once. The documentation does not specify clinical-review turnaround, preparation time, carrier, transit window, tracking arrangements, or refrigeration procedures. Including shipping in the advertised price is useful, but it does not answer those operational questions. Readers should ask who will dispense the prescription and who is responsible for resolving a delayed or compromised delivery.

Fitish RX directs damaged, defective, or incorrect-order concerns to theclinic@fitish.com, but the contact language does not promise a specific replacement or refund remedy. FDA separately advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. That is an explicit action point, not a basis for assuming this provider has experienced a cold-chain failure.

Sources: [14] [8] [10] [1]

Follow-up is documented, but responsiveness is not measured

Fitish RX advertises regular check-ins, progress tracking, and direct messaging with the care team. Its tirzepatide page says portal support includes questions, clinician-directed adjustments, and ongoing assistance at no added cost. These are substantive service promises rather than merely an invitation to purchase refills. However, the reviewed documentation does not establish how frequently check-ins occur, who answers each type of message, or how quickly clinical concerns receive a response.

The contact page separates treatment and product questions at theclinic@fitish.com, orders and existing-patient matters at orders@fitish.com, and general questions at info@fitish.com. It also lists 1-800-576-8990 and a Fitish, LLC mailing address at 2311 East Loop 820 North, Fort Worth, Texas 76118. Multiple contact paths are useful, but an available email address does not establish round-the-clock staffing or a guaranteed clinical response time.

NIDDK describes follow-up as involving tolerance and response, with treatment choices also considering health conditions, other medicines, side effects, and cost. Readers can use our guide to clinical follow-up to distinguish medical oversight from payment administration. Fitish RX’s privacy notice also recognizes access to health records, including an electronic copy where readily producible, subject to limited exceptions and a possible reasonable, cost-based fee. That could matter when coordinating or transferring care.

Sources: [5] [14] [10] [7] [2]

The missing terms are practical evidence gaps

The website terms allow termination by notifying the company that services are no longer wanted or by ceasing use of the site. That general language does not explain how to stop future clinical shipments or charges. The consulted documentation does not establish automatic-renewal terms, billing dates, cancellation notice deadlines, pauses, or treatment-specific procedures. A monthly shipping cadence should not be used to infer either a subscription or the absence of one.

The terms refer returns and exchanges to a Return Policy, but that policy’s operative conditions were not available in the consulted documentation. There is no clear documented answer here for refunds after clinical denial, unused supplies, or a partially completed bundle. Cancellation and refund are different questions. Similarly, replying STOP ends the SMS service and generates a confirmation message; it is not documented as a method for canceling clinical care, charges, or deliveries.

The most useful next step is a written explanation tied to the exact selected program: what is charged initially, when another charge can occur, what happens if no prescription is issued, and how future fulfillment is stopped. Readers should also request the dispensing pharmacy’s identity, state availability, and support expectations. These gaps do not prove the service lacks workable policies; they mean the public documentation reviewed here does not establish them.

Sources: [9] [6] [14]

Questions & answers

Does Fitish RX guarantee a prescription after payment?

No prescription guarantee is documented. Fitish RX describes an online intake followed by licensed-provider review, with medication available only when clinically appropriate. Its advertised standard prices include medication if approved. The consulted pages do not clearly explain the financial outcome if a clinician declines to prescribe, so ask what is collected before review and whether any portion is refundable.

Sources: [8] [14]

Are Fitish RX’s oral tirzepatide tablets FDA approved?

No. Fitish RX explicitly says its compounded oral tirzepatide is not FDA approved and that FDA-approved tirzepatide is available only as an injection. The tablets cost $339 per monthly supply before any advertised bundle pricing. Research on a studied injectable regimen does not establish outcomes for these tablets. Ask for evidence specific to the oral preparation rather than relying on the ingredient name.

Sources: [11] [4]

Does a three- or six-month bundle require full prepayment?

The consulted pages do not establish that. They show monthly bundle rates and say pricing is applied during intake, but do not clearly state the payment schedule, total collected initially, or minimum commitment. Do not assume either installment billing or mandatory prepayment. Request those terms for the specific semaglutide, injectable tirzepatide, or oral tirzepatide bundle before authorizing payment.

Sources: [8] [14] [11]

Is the microdosing program a less expensive weight-loss plan?

That is not how its dedicated page defines it. Fitish RX says microdosing is for wellness and cosmetic support, not weight loss or weight management. It lists $179 for semaglutide and $269 for tirzepatide per 28-day supply, while also using monthly language elsewhere. The stated purpose, supply interval, included services, and supporting evidence need clarification rather than comparison on price alone.

Sources: [15]

Can I use insurance or assume service is available in my state?

Fitish RX says it does not accept insurance and is a cash-pay telehealth service. The consulted pages do not establish a complete list of states served. Its Texas mailing address is not evidence of nationwide clinical availability, and its terms allow geographic restrictions. Confirm access for your location before enrollment; insurance acceptance and geographic authorization are separate questions.

Sources: [5] [9] [10]

Who should handle a medication or shipping problem?

Fitish RX lists theclinic@fitish.com for treatment and product issues, including damaged, defective, or incorrect orders, and orders@fitish.com for order and existing-patient matters. It does not document a specific refund or replacement guarantee in that contact language. If an injectable GLP-1 arrives warm or inadequately refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy to resolve the concern.

Sources: [10] [1]

Our assessment

Fitish RX provides a reasonably concrete public account of its product menu, standard prices, conditional prescribing, included shipping, and portal support. Its explicit disclosures about compounded products and oral tirzepatide are useful. Those strengths do not establish clinical outcomes for its formulations, validate microdosing claims, or independently verify its pharmacies and clinicians. The weakest documentary areas are payment commitments, cancellation and refund procedures, pharmacy identity, and geographic availability. A reader considering the service should obtain those operational terms in writing and ask what evidence supports the exact preparation and intended use. Clear service promises and clinical proof remain separate standards.

Visit Fitish RX’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Fitish RX Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the ingredient name

02What clinical trials can—and cannot—add

03Who reviews an application and provides care

04Microdosing has a separate purpose—and an unresolved evidence gap

05Published prices are concrete; payment commitments are less clear

06Pharmacy and delivery claims need operational detail

07Follow-up is documented, but responsiveness is not measured

08The missing terms are practical evidence gaps